Kura Oncology Inc. (NASDAQ:KURA) shares dropped 6.8% during mid-day trading on Wednesday . The company traded as low as $3.80 and last traded at $3.81, with a volume of 70,145 shares trading hands. The stock had previously closed at $4.09.

KURA has been the topic of a number of recent research reports. Oppenheimer Holdings Inc. reissued an “outperform” rating and issued a $16.00 target price on shares of Kura Oncology in a report on Tuesday, June 21st. Zacks Investment Research upgraded Kura Oncology from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a research note on Wednesday, July 13th.

The firm’s market cap is $72.10 million. The firm’s 50 day moving average price is $3.32 and its 200-day moving average price is $3.76.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Wednesday, May 11th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.01. Analysts anticipate that Kura Oncology Inc. will post ($1.70) EPS for the current year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.